Advertisement

Topics

Aravive Biologics, Inc. Company Profile

00:51 EDT 17th June 2019 | BioPortfolio

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer malignancies by promoting tumor metastasis and cell survival. Aravive Biologics has generated strong preclinical data for its lead drug candidate, Aravive-S6, in both acute myeloid leukemia (AML) and solid tumors including ovarian, pancreatic, and breast cancers. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT). For more information, please visit our website at http://www.aravive.com.


News Articles [610 Associated News Articles listed on BioPortfolio]

Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial of AVB-S6-500 in Platinum-Resistant Recurrent Ovarian Cancer

Aravive (Nasdaq:ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500...

Aravive begins Phase Ib part of ovarian cancer drug trial

Aravive has commenced the Phase Ib portion of a clinical trial evaluating the combination of AVB-S6-500 with standard-of-care to treat...Read More... The post Aravive begins Phase Ib part of ovarian c...

Aravive Receives Additional $2.6M Disbursement from the Cancer Prevention and Research Institute of Texas $ARAV https://finance.yahoo.com/news/aravive-receives-additional-2-6-120000697.html …

Aravive Receives Additional $2.6M Disbursement from the Cancer Prevention and Research Institute of Texas $ARAV https://finance.yahoo.com/news/aravive-receives-additional-2-6-120000697.html &he...

Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference

HOUSTON, March 05, 2019 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming ...

CORRECTING AND REPLACING – Aravive Announces Participation at Cowen and Company 39th Annual Health Care Conference

HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming ...

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel ...

SHANGHAI, Dec. 9, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development a...

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

SHANGHAI and DUNDALK, Ireland, Dec. 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics...

DSM Biologics: Karen King on New Technology and Reducing the Cost of Medicines

In this episode of PharmaTelevision News Review, Fintan Walton talks with Karen King, President and Business Unit Director of DSM Biologics. Filmed at BioChicago 2010 in Chicago, USA, they discuss: ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Atryn [revo bioloigics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for rec...

Anticoagulant citrate dextrose a [citra labs]

ACD-A Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., PN 9350, 30 mL NDC 23731-6051-3

Rejuvesol [citra labs llc]

rejuvesol red blood cell processing solution

PubMed Articles [104 Associated PubMed Articles listed on BioPortfolio]

Biosimilars in India; Current Status and Future Perspectives.

Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar ...

Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics.

It is unclear whether immunomodulators or biologics, with the exception of corticosteroids, can be risk factors for postoperative infectious complications of ulcerative colitis (UC). Moreover, many im...

Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics.

Biologics, especially monoclonal antibodies, are increasingly important in the pharmaceutical marketplace. Population pharmacokinetic (PK) analyses could be useful to guide the need for dose adjustmen...

Cutaneous lymphomas appearing under biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.

Controversy exists regarding the risk and prognosis of lymphomas under biologics . Risk evaluation must consider the underlying medical condition -as chronic inflammatory diseases are associated with ...

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly t...

Clinical Trials [90 Associated Clinical Trials listed on BioPortfolio]

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Companies [283 Associated Companies listed on BioPortfolio]

Aravive Biologics, Inc.

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while ...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

Prellis Biologics, Inc.

Prellis Biologics, Inc. developed the first holographic printing system able to match and accurately replicate human organ and tissue structures for R&D and organ transplan...

More Information about "Aravive Biologics, Inc." on BioPortfolio

We have published hundreds of Aravive Biologics, Inc. news stories on BioPortfolio along with dozens of Aravive Biologics, Inc. Clinical Trials and PubMed Articles about Aravive Biologics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aravive Biologics, Inc. Companies in our database. You can also find out about relevant Aravive Biologics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record